I. Porras

发表

Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

M. Dueñas, P. Sánchez‐Rovira, A. Lozano, 2000, Clinical breast cancer.

Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC

P. Sánchez‐Rovira, R. Dueñas, A. Lozano, 1999 .

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium‐223 Therapy: Experience in a Cohort of Patients With Metastatic Castration‐Resistant Prostate Cancer

J. Carles, B. Mellado, J. Pérez-Gracia, 2018, Clinical genitourinary cancer.

Genetic variants in the renin–angiotensin system predict response to bevacizumab in cancer patients

E. Aranda, A. Rodríguez-Ariza, L. López-Sánchez, 2015, European journal of clinical investigation.

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

F. Rojo, J. Albanell, A. Lluch, 2014, British Journal of Cancer.

Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.

E. Carrasco, P. Sánchez‐Rovira, R. Dueñas, 2001, Oncology.

Neoadjuvant gemcitabine therapy for breast cancer.

P. Sánchez‐Rovira, R. Dueñas, A. Lozano, 2002, Clinical breast cancer.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

E. Dalmau, S. Morales, A. Antón, 2013, Clinical and Translational Oncology.

SEOM clinical guideline thyroid cancer (2019)

E. Gallardo, T. Ramón Y Cajal, J. Capdevila, 2020, Clinical and Translational Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).

I. Matos, J. Capdevila, E. Grande, 2017, European journal of endocrinology.